<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="An example is a variant of coronaviruses (CoV) causing severe" exact="acute" post="respiratory syndrome (SARS), named SARS-CoV-2. Some antiviral drugs, such"/>
 <result pre="example is a variant of coronaviruses (CoV) causing severe acute" exact="respiratory" post="syndrome (SARS), named SARS-CoV-2. Some antiviral drugs, such as"/>
 <result pre="is a variant of coronaviruses (CoV) causing severe acute respiratory" exact="syndrome" post="(SARS), named SARS-CoV-2. Some antiviral drugs, such as remdesivir"/>
 <result pre="aimed at the identification of the molecular mechanisms of human" exact="immunodeficiency" post="virus type 1 (HIV-1) infection and the development of"/>
 <result pre="the identification of the molecular mechanisms of human immunodeficiency virus" exact="type 1" post="(HIV-1) infection and the development of novel therapeutic approaches"/>
 <result pre="the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1)" exact="infection" post="and the development of novel therapeutic approaches against HIV-1,"/>
 <result pre="46 targets, which can be essential for the development of" exact="infections" post="caused by SARS-CoV-2 and HIV-1. We show that SARS-CoV-2"/>
 <result pre="Introduction Studying viruses that infect human beings is vital because" exact="viral" post="infections can spread within the global population. For several"/>
 <result pre="Studying viruses that infect human beings is vital because viral" exact="infections" post="can spread within the global population. For several centuries,"/>
 <result pre="the global population. For several centuries, measles, poliomyelitis, rotavirus, human" exact="immunodeficiency" post="virus, and different respiratory viruses, including influenza, parainfluenza, adenoviruses,"/>
 <result pre="several centuries, measles, poliomyelitis, rotavirus, human immunodeficiency virus, and different" exact="respiratory" post="viruses, including influenza, parainfluenza, adenoviruses, and coronaviruses, have attacked"/>
 <result pre="significant epidemic or even pandemic diseases [1,2]. SARS-CoV-2 causes severe" exact="acute" post="respiratory syndrome and leads to diverse complications, being especially"/>
 <result pre="epidemic or even pandemic diseases [1,2]. SARS-CoV-2 causes severe acute" exact="respiratory" post="syndrome and leads to diverse complications, being especially dangerous"/>
 <result pre="or even pandemic diseases [1,2]. SARS-CoV-2 causes severe acute respiratory" exact="syndrome" post="and leads to diverse complications, being especially dangerous for"/>
 <result pre="with different comorbidities. Starting from the end of January, COronaVIrus" exact="Disease" post="2019 (COVID-19) has spread all over the world and"/>
 <result pre="repurposing of drugs initially developed against other viruses, such as" exact="hepatitis C," post="HIV-1, influenza, etc., along with host-targeted drugs such as"/>
 <result pre="as hydroxychloroquine and azithromycin [4,5,6,7,8,9]. Overcoming the challenges of novel" exact="viral" post="infections requires a fast and effective search for novel"/>
 <result pre="hydroxychloroquine and azithromycin [4,5,6,7,8,9]. Overcoming the challenges of novel viral" exact="infections" post="requires a fast and effective search for novel therapeutic"/>
 <result pre="perspective strategy is focused on finding proteins involved in the" exact="infection" post="process caused by both studied and well-known agents using"/>
 <result pre="known antiviral drugs, including those employed for the treatment of" exact="viral hepatitis" post="C and antiretroviral drugs, to treat SARS-CoV-2 [7,8,9]. There"/>
 <result pre="antiviral drugs, including those employed for the treatment of viral" exact="hepatitis C" post="and antiretroviral drugs, to treat SARS-CoV-2 [7,8,9]. There are"/>
 <result pre="in patients with COVID-19 [16] and can be associated with" exact="disease" post="progression [16]. The analysis of the available information provides"/>
 <result pre="are a lot of data on the molecular mechanisms of" exact="HIV infection," post="regarding multiple pathways of virusâ€&quot;host interactions and the development"/>
 <result pre="activities, as well as proteins associated with molecular mechanisms of" exact="disease" post="development [17,18]. In this study, we applied text and"/>
 <result pre="gastrointestinal tract [23]. There are therapeutic strategies to combat HIV-1" exact="infection" post="in addition to combination antiretroviral therapy, which is currently"/>
 <result pre="used to treat HIV-infection [24]. Other approaches to combat HIV-1" exact="infection" post="include novel strategies such as disrupting the CCR5 gene"/>
 <result pre="CD4+ T cells or HSCs using CRISPR/Cas9 genome editing [26,27]." exact="Viral" post="RNA genome degradation and inhibition of viral gene expression"/>
 <result pre="genome editing [26,27]. Viral RNA genome degradation and inhibition of" exact="viral" post="gene expression is another promising strategy to prevent the"/>
 <result pre="The therapeutic effects of medicines applied for the treatment of" exact="rheumatoid arthritis" post="[31] along with those of some other drugs such"/>
 <result pre="therapeutic effects of medicines applied for the treatment of rheumatoid" exact="arthritis" post="[31] along with those of some other drugs such"/>
 <result pre="on SARS-CoV-2 have generated interest in identifying similar mechanisms of" exact="viral infection" post="shared by SARS-CoV-2 and HIV-1, in particular their effects"/>
 <result pre="SARS-CoV-2 have generated interest in identifying similar mechanisms of viral" exact="infection" post="shared by SARS-CoV-2 and HIV-1, in particular their effects"/>
 <result pre="comorbidities [11,33,34,35], in particular, by causing the so-called cytokine release" exact="syndrome" post="[33]. In this study, we will also discuss the"/>
 <result pre="proteins that play a role in both HIV-1 and SARS-CoV-2" exact="infections" post="are presented in Table 1. For a full list,"/>
 <result pre="of the identified proteins in the molecular mechanisms of these" exact="infections" post="was analyzed. Besides the interpretation of the role of"/>
 <result pre="HIV-1, and other viruses. This result was confirmed by a" exact="disease" post="enrichment analysis, which was performed based on geneâ€&quot;disease associations"/>
 <result pre="based on geneâ€&quot;disease associations using the DisGeNet database [38]. Various" exact="viral" post="infections and related diseases, including SARS-CoV-2 and HIV-1 infections,"/>
 <result pre="on geneâ€&quot;disease associations using the DisGeNet database [38]. Various viral" exact="infections" post="and related diseases, including SARS-CoV-2 and HIV-1 infections, were"/>
 <result pre="to that of SARS-CoV-2, we also evaluated texts associated with" exact="Dengue" post="virus and determined an overlap between the proteins relevant"/>
 <result pre="a similar profile of molecular pathways for proteins shared by" exact="Dengue" post="virus and SARS-CoV-2 to that for proteins shared by"/>
 <result pre="studies showing the involvement of the immune system in SARS-CoV-2" exact="disease" post="progression [15,16]. Also, some of the pathways, for instance,"/>
 <result pre="beclin-1 in autophagy as one of the molecular mechanisms of" exact="viral" post="pathogenesis was discussed for both coronaviruses and HIV-1 [42,43]."/>
 <result pre="HIV-1 [42,43]. The inhibition of beclin-1 can help to reduce" exact="viral" post="replication of MERS-CoV (Middle East respiratory syndrome coronavirus) [44]."/>
 <result pre="can help to reduce viral replication of MERS-CoV (Middle East" exact="respiratory" post="syndrome coronavirus) [44]. Despite these findings, it is supposed"/>
 <result pre="help to reduce viral replication of MERS-CoV (Middle East respiratory" exact="syndrome" post="coronavirus) [44]. Despite these findings, it is supposed that"/>
 <result pre="machinery is not considered as a promising one to combat" exact="viral" post="infections including HIV-1 infection and COVID-19 [45]. The proteins"/>
 <result pre="is not considered as a promising one to combat viral" exact="infections" post="including HIV-1 infection and COVID-19 [45]. The proteins cathepsin"/>
 <result pre="as a promising one to combat viral infections including HIV-1" exact="infection" post="and COVID-19 [45]. The proteins cathepsin B and L,"/>
 <result pre="B and L, which are endosomal proteases, are responsible for" exact="viral" post="fusion and the release of the viral genome into"/>
 <result pre="are responsible for viral fusion and the release of the" exact="viral" post="genome into the cytoplasm of human cells [46]. The"/>
 <result pre="used by HIV-1 variants that do not require CD4 for" exact="infection" post="[49]. There is evidence that an interaction of SARS-CoV-2"/>
 <result pre="SARS-CoV-2 with cathepsin L is essential for SARS-CoV-2 entry [50]." exact="Selective" post="inhibitors of cathepsin L can be considered for the"/>
 <result pre="selective cathepsin L inhibitors because active cathepsin S can assist" exact="viral" post="release and MHC-I- and MHC-II-mediated antigen presentation as well"/>
 <result pre="that for herpesviruses, the role of cathepsin L in releasing" exact="viral" post="particles was reported [52], giving rise to the hypothesis"/>
 <result pre="that secretion of cathepsin B by HIV-infected macrophages leads to" exact="neuronal" post="internalization and induces the progression of neuronal dysfunctions [54,55]."/>
 <result pre="macrophages leads to neuronal internalization and induces the progression of" exact="neuronal" post="dysfunctions [54,55]. Therefore, cathepsin B expressed in different tissues"/>
 <result pre="different tissues is involved in several different molecular pathways of" exact="disease" post="progression. E3 ubiquitin ligase TRIM25 participates in the regulation"/>
 <result pre="of SARS-CoV-2 [58] was found to bind TRIM25, thereby inhibiting" exact="type 1" post="interferon production [56]. TRIM25 was also shown to be"/>
 <result pre="also shown to be required for the activity of a" exact="type I" post="interferon-inducible host factor ZAP, which specifically inhibits the replication"/>
 <result pre="response to the infection, especially it can be observed during" exact="viral" post="infections. SARS-CoV-2 affects the immune response, leading to a"/>
 <result pre="pathways and found to appear in both SARS-CoV-2 and HIV-1" exact="infections" post="(Figure 3). Toll-like receptors 3 (TLR3) and 7 (TLR7)"/>
 <result pre="inhibition of HIV-1 replication, which may help to treat latent" exact="infections" post="[70]. The role of TLR3 and TLR7 in the"/>
 <result pre="these results, the majority of proteins are related to inflammation," exact="autoimmune" post="disorders and cancer (Figure 4). It seems surprising that"/>
 <result pre="majority of proteins are related to inflammation, autoimmune disorders and" exact="cancer" post="(Figure 4). It seems surprising that most of the"/>
 <result pre="the found targets of existing drugs are not related to" exact="infectious diseases" post="but, rather, are associated with inflammation, cancer, or immune"/>
 <result pre="infectious diseases but, rather, are associated with inflammation, cancer, or" exact="immune disorders." post="However, since we analyzed virusâ€&quot;host interactions, we could expect"/>
 <result pre="those that affect the host immune system. The association between" exact="cancer" post="development and inflammation has been discussed in several studies"/>
 <result pre="studies [72,73,74,75]. Moreover, the role of the targets associated with" exact="autoimmune diseases" post="in the development of cancer has been described [74]."/>
 <result pre="the targets associated with autoimmune diseases in the development of" exact="cancer" post="has been described [74]. Based on the analysis of"/>
 <result pre="proteins, their role in inflammation and the immune response during" exact="infection" post="is well studied [76]. The second group contains a"/>
 <result pre="medicines are not known. The obtained results were confirmed by" exact="disease" post="enrichment analysis based on geneâ€&quot;disease associations using the DisGeNet"/>
 <result pre="the DisGeNet database. We manually analyzed the top 30 enriched" exact="disease" post="terms and classified them in four groups (see Supplementary"/>
 <result pre="terms related to viruses and bacteria, e.g., SARS, HIV infections," exact="hepatitis" post="B and C, cytomegalovirus infections, influenza, tuberculosis, and others."/>
 <result pre="tuberculosis, and others. The second group is related to inflammatory" exact="respiratory" post="diseases: asthma, chronic obstructive airway disease, and pneumonia. The"/>
 <result pre="The second group is related to inflammatory respiratory diseases: asthma," exact="chronic" post="obstructive airway disease, and pneumonia. The third group is"/>
 <result pre="airway disease, and pneumonia. The third group is related to" exact="cancer" post="diseases, whereas the fourth group includes all other diseases,"/>
 <result pre="all other diseases, which are associated with inflammation, e.g., atherosclerosis," exact="systemic" post="lupus erythematosus, and rheumatoid arthritis. All 46 proteins appeared"/>
 <result pre="other diseases, which are associated with inflammation, e.g., atherosclerosis, systemic" exact="lupus erythematosus," post="and rheumatoid arthritis. All 46 proteins appeared to be"/>
 <result pre="are associated with inflammation, e.g., atherosclerosis, systemic lupus erythematosus, and" exact="rheumatoid arthritis." post="All 46 proteins appeared to be associated with at"/>
 <result pre="full list of proteins related to the development of SARS-CoV-1" exact="infection" post="only in Table S3 of the Supplementary Materials. Summarizing"/>
 <result pre="and HIV-1-host interactions. The first group represents proteins responsible for" exact="viral" post="entry in human cells, which are the same for"/>
 <result pre="are important for processes such as blood coagulation. Third, some" exact="viral" post="proteins can interact with human proteins in a close"/>
 <result pre="abstracts and full texts from NCBI PubMed and NCBI PubMed" exact="Central" post="(PMC) repositories. We used the application-programming interface (API) available"/>
 <result pre="PubMed electronic library (PMIDs) or the identifiers of NCBI PubMed" exact="Central" post="(PMCIDs). The queries allowed identifying over 200 PMIDs and"/>
 <result pre="a collection of unbiased corpora (i.e., corpora which are not" exact="limited" post="by using several journals). Full texts of SARS-PMC and"/>
 <result pre="on the corpus used for training the algorithm and an" exact="external" post="test set â€œHIV-RT-inhibitor corpusâ€� containing 250 abstracts. The average"/>
 <result pre="the pathways and molecular mechanisms responsible for infection, invasion, and" exact="disease" post="progression similarly or identically for HIV-1 and SARS-CoV-2. The"/>
 <result pre="carried out using NCBI PubMed electronic library and the UniProt," exact="Protein" post="Atlas, and Integrity databases. To identify signaling pathways, first"/>
 <result pre="mechanisms that may be essential for the development of the" exact="infections" post="caused by SARS-CoV-2 and HIV-1 and demonstrated the usefulness"/>
 <result pre="be associated with mechanisms related to both HIV-1 and SARS-CoV-2" exact="infections" post="and to several different processes of pathogenesis, from virus"/>
 <result pre="human proteins identified as having impact on SARS-CoV-2 and HIV-1" exact="infections" post="development, Table S2: The proteins found as belonging to"/>
 <result pre="List of human proteins involved in the development of the" exact="infection" post="caused by SARS-CoV-1 according to the text and data"/>
 <result pre="of the manuscript. Funding This research was funded by the" exact="Russian" post="Science Foundation, grant number 19-75-10097. Conflicts of Interest The"/>
 <result pre="5.CilibertoG.ManciniR.PaggiM.G.Drug repurposing against COVID-19: Focus on anticancer agentsJ. Exp. Clin." exact="Cancer" post="Res.2020398610.1186/s13046-020-01590-232398164 6.SayadB.SobhaniM.KhodarahmiR.Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why"/>
 <result pre="COVID-19: Initial assessmentJ. Int. AIDS Soc.202023e2548910.1002/jia2.2548932293807 12.KimJ.-W.KimE.J.KwonH.H.JungC.Y.KimK.C.ChoeJ.-Y.HongH.-L.Lopinavir-ritonavir versus hydroxychloroquine for" exact="viral" post="clearance and clinical improvement in patients with mild to"/>
 <result pre="and clinical improvement in patients with mild to moderate coronavirus" exact="disease" post="2019Korean J. Intern. Med.202010.3904/kjim.2020.22432536150 13.PanagopoulosP.PetrakisV.PanopoulouM.TrypsianisG.PenlioglouT.PnevmatikosI.PapazoglouD.Lopinavir/ritonavir as a third agent"/>
 <result pre="through its spike protein-mediated membrane fusionCell. Mol. Immunol.202010.1038/s41423-020-0424-9 16.TanL.WangQ.ZhangD.DingJ.HuangQ.TangY.-Q.WangQ.MiaoH.Lymphopenia predicts" exact="disease" post="severity of COVID-19: A descriptive and predictive studySignal. Transduct."/>
 <result pre="HIV ReplicationCurr. Top. Med. Chem.2016161167119010.2174/156802661566615090111510626324041 23.MonacoD.C.EndeZ.HunterE.Virus-Host Gene Interactions Define HIV-1" exact="Disease" post="ProgressionCurr. Top. Microbiol. Immunol.2017407316310.1007/82_2017_3328653187 24.AstutiI.YsrafilSevere Acute Respiratory Syndrome Coronavirus"/>
 <result pre="Gene Interactions Define HIV-1 Disease ProgressionCurr. Top. Microbiol. Immunol.2017407316310.1007/82_2017_3328653187 24.AstutiI.YsrafilSevere" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral"/>
 <result pre="Interactions Define HIV-1 Disease ProgressionCurr. Top. Microbiol. Immunol.2017407316310.1007/82_2017_3328653187 24.AstutiI.YsrafilSevere Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure"/>
 <result pre="Define HIV-1 Disease ProgressionCurr. Top. Microbiol. Immunol.2017407316310.1007/82_2017_3328653187 24.AstutiI.YsrafilSevere Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2): An overview of viral structure and"/>
 <result pre="24.AstutiI.YsrafilSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of" exact="viral" post="structure and host responseDiabetes Metab. Syndr.20201440741210.1016/j.dsx.2020.04.02032335367 25.TitanjiB.K.PillayD.JollyC.Combination antiretroviral therapy"/>
 <result pre="antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human" exact="immunodeficiency" post="virus-1J. Gen. Virol.20179882183410.1099/jgv.0.00072828141491 26.HoltN.WangJ.KimK.FriedmanG.WangX.TaupinV.CrooksG.M.KohnD.B.GregoryP.D.HolmesM.C.et al.Human hematopoietic stem/progenitor cells modified"/>
 <result pre="Autoimmun.202010246810.1016/j.jaut.2020.10246832317220 33.PedersenS.F.HoY.C.SARS-CoV-2: A storm is ragingJ. Clin. Invest.2020130220210.1172/JCI13764732217834 34.ClayC.C.DonartN.FomukongN.KnightJ.B.OverheimK.TipperJ.Van WestrienenJ.HahnF.HarrodK.S.Severe" exact="acute" post="respiratory syndrome-coronavirus infection in aged nonhuman primates is associated"/>
 <result pre="33.PedersenS.F.HoY.C.SARS-CoV-2: A storm is ragingJ. Clin. Invest.2020130220210.1172/JCI13764732217834 34.ClayC.C.DonartN.FomukongN.KnightJ.B.OverheimK.TipperJ.Van WestrienenJ.HahnF.HarrodK.S.Severe acute" exact="respiratory" post="syndrome-coronavirus infection in aged nonhuman primates is associated with"/>
 <result pre="storm is ragingJ. Clin. Invest.2020130220210.1172/JCI13764732217834 34.ClayC.C.DonartN.FomukongN.KnightJ.B.OverheimK.TipperJ.Van WestrienenJ.HahnF.HarrodK.S.Severe acute respiratory syndrome-coronavirus" exact="infection" post="in aged nonhuman primates is associated with modulated pulmonary"/>
 <result pre="syndrome-coronavirus infection in aged nonhuman primates is associated with modulated" exact="pulmonary" post="and systemic immune responsesImmun. Ageing201411410.1186/1742-4933-11-424642138 35.ZhouG.ChenS.ChenZ.Advances in COVID-19: The"/>
 <result pre="in aged nonhuman primates is associated with modulated pulmonary and" exact="systemic" post="immune responsesImmun. Ageing201411410.1186/1742-4933-11-424642138 35.ZhouG.ChenS.ChenZ.Advances in COVID-19: The virus, the"/>
 <result pre="diseases and drugsNucleic Acids Res.201745D353D36110.1093/nar/gkw109227899662 38.PiÃ±eroJ.RamÃ­rez-AnguitaJ.M.SaÃ¼ch-PitarchJ.RonzanoF.CentenoE.SanzF.FurlongL.I.The DisGeNET knowledge platform for" exact="disease" post="genomics: 2019 updateNucleic Acids Res.202048D845D85510.1093/nar/gkz102131680165 39.Clarivate Analytics Integrity Home"/>
 <result pre="Blocked by a Clinically Proven Protease InhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 48.DivaniA.A.AndalibS.Di NapoliM.LattanziS.HussainM.S.BillerJ.McCulloughL.D.AzarpazhoohM.R.SeletskaA.MayerS.A.et al.Coronavirus" exact="Disease" post="2019 and Stroke: Clinical Manifestations and Pathophysiological InsightsJ. Stroke"/>
 <result pre="Manifestations and Pathophysiological InsightsJ. Stroke Cerebrovasc. Dis.20202910494110.1016/j.jstrokecerebrovasdis.2020.104941 49.YoshiiH.KamiyamaH.GotoK.OishiK.KatunumaN.TanakaY.HayashiH.MatsuyamaT.SatoH.YamamotoN.et al.CD4-independent human" exact="immunodeficiency" post="virus infection involves participation of endocytosis and cathepsin BPLoS"/>
 <result pre="and Pathophysiological InsightsJ. Stroke Cerebrovasc. Dis.20202910494110.1016/j.jstrokecerebrovasdis.2020.104941 49.YoshiiH.KamiyamaH.GotoK.OishiK.KatunumaN.TanakaY.HayashiH.MatsuyamaT.SatoH.YamamotoN.et al.CD4-independent human immunodeficiency" exact="virus infection" post="involves participation of endocytosis and cathepsin BPLoS ONE20116e1935210.1371/journal.pone.001935221541353 50.OuX.LiuY.LeiX.LiP.MiD.RenL.GuoL.GuoR.ChenT.HuJ.et"/>
 <result pre="Pathophysiological InsightsJ. Stroke Cerebrovasc. Dis.20202910494110.1016/j.jstrokecerebrovasdis.2020.104941 49.YoshiiH.KamiyamaH.GotoK.OishiK.KatunumaN.TanakaY.HayashiH.MatsuyamaT.SatoH.YamamotoN.et al.CD4-independent human immunodeficiency virus" exact="infection" post="involves participation of endocytosis and cathepsin BPLoS ONE20116e1935210.1371/journal.pone.001935221541353 50.OuX.LiuY.LeiX.LiP.MiD.RenL.GuoL.GuoR.ChenT.HuJ.et"/>
 <result pre="B/cathepsin B in HIV replication and neuropathogenesisCurr. HIV Res.20141211112010.2174/1570162X1266614052612024924862331 54.Cantres-RosarioY.M.Ortiz-RodrÃ­guezS.C.Santos-FigueroaA.G.PlaudM.NegronK.CottoB.LangfordD.MelendezL.M.HIV" exact="Infection" post="Induces Extracellular Cathepsin B Uptake and Damage to NeuronsSci."/>
 <result pre="B and cystatin B in HIV-seropositive women are associated with" exact="infection" post="and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe Acute Respiratory Syndrome"/>
 <result pre="women are associated with infection and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon"/>
 <result pre="are associated with infection and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production"/>
 <result pre="associated with infection and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by"/>
 <result pre="with infection and HIV-1-associated neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering"/>
 <result pre="neurocognitive disordersAIDS20132734735610.1097/QAD.0b013e32835b3e4723291538 56.HuY.LiW.GaoT.CuiY.JinY.LiP.MaQ.LiuX.CaoC.The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits" exact="Type I" post="Interferon Production by Interfering with TRIM25-Mediated RIG-I UbiquitinationJ. Virol.20179110.1128/JVI.02143-1628148787"/>
 <result pre="61.MuemaD.M.AkilimaliN.A.NdumnegoO.C.RasehloS.S.DurgiahR.OjwachD.B.A.IsmailN.DongM.MoodleyA.DongK.L.et al.Association between the cytokine storm, immune cell dynamics, and" exact="viral" post="replicative capacity in hyperacute HIV infectionBMC Med.2020188110.1186/s12916-020-01529-632209092 62.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement Activation"/>
 <result pre="capacity in hyperacute HIV infectionBMC Med.2020188110.1186/s12916-020-01529-632209092 62.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement Activation Contributes to" exact="Severe" post="Acute Respiratory Syndrome Coronavirus PathogenesismBio2018910.1128/mBio.01753-1830301856 63.NitkiewiczJ.BorjabadA.MorgelloS.MurrayJ.ChaoW.EmdadL.FisherP.B.PotashM.J.VolskyD.J.HIV induces expression of"/>
 <result pre="in hyperacute HIV infectionBMC Med.2020188110.1186/s12916-020-01529-632209092 62.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement Activation Contributes to Severe" exact="Acute" post="Respiratory Syndrome Coronavirus PathogenesismBio2018910.1128/mBio.01753-1830301856 63.NitkiewiczJ.BorjabadA.MorgelloS.MurrayJ.ChaoW.EmdadL.FisherP.B.PotashM.J.VolskyD.J.HIV induces expression of complement"/>
 <result pre="hyperacute HIV infectionBMC Med.2020188110.1186/s12916-020-01529-632209092 62.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement Activation Contributes to Severe Acute" exact="Respiratory" post="Syndrome Coronavirus PathogenesismBio2018910.1128/mBio.01753-1830301856 63.NitkiewiczJ.BorjabadA.MorgelloS.MurrayJ.ChaoW.EmdadL.FisherP.B.PotashM.J.VolskyD.J.HIV induces expression of complement component"/>
 <result pre="HIV infectionBMC Med.2020188110.1186/s12916-020-01529-632209092 62.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement Activation Contributes to Severe Acute Respiratory" exact="Syndrome" post="Coronavirus PathogenesismBio2018910.1128/mBio.01753-1830301856 63.NitkiewiczJ.BorjabadA.MorgelloS.MurrayJ.ChaoW.EmdadL.FisherP.B.PotashM.J.VolskyD.J.HIV induces expression of complement component C3"/>
 <result pre="and reduces HIV-1 reservoirsJ. Clin. Investig.20181284387439610.1172/JCI9900530148455 70.LimS.-Y.OsunaC.E.HraberP.T.HesselgesserJ.GeroldJ.M.BarnesT.L.SanisettyS.SeamanM.S.LewisM.G.GeleziunasR.et al.TLR7 agonists induce" exact="transient" post="viremia and reduce the viral reservoir in SIV-infected rhesus"/>
 <result pre="Investig.20181284387439610.1172/JCI9900530148455 70.LimS.-Y.OsunaC.E.HraberP.T.HesselgesserJ.GeroldJ.M.BarnesT.L.SanisettyS.SeamanM.S.LewisM.G.GeleziunasR.et al.TLR7 agonists induce transient viremia and reduce the" exact="viral" post="reservoir in SIV-infected rhesus macaques on antiretroviral therapySci. Transl."/>
 <result pre="Major Cytokines, and Cancer-Related InflammationMol. Ther. Nucleic Acids20202060662010.1016/j.omtn.2020.04.00232348938 74.GiatE.EhrenfeldM.ShoenfeldY.Cancer and" exact="autoimmune" post="diseasesAutoimmun. Rev.2017161049105710.1016/j.autrev.2017.07.02228778707 75.YinQ.WyattC.J.HanT.SmalleyK.S.M.WanL.ITCH as a potential therapeutic target in"/>
 <result pre="Rev.2017161049105710.1016/j.autrev.2017.07.02228778707 75.YinQ.WyattC.J.HanT.SmalleyK.S.M.WanL.ITCH as a potential therapeutic target in human cancersSemin." exact="Cancer" post="Biol.202010.1016/j.semcancer.2020.03.00332165318 76.LiuA.Y.Infectious Implications of Interleukin-1, Interleukin-6, and T Helper"/>
 <result pre="Cancer Biol.202010.1016/j.semcancer.2020.03.00332165318 76.LiuA.Y.Infectious Implications of Interleukin-1, Interleukin-6, and T Helper" exact="Type 2" post="InhibitionInfect. Dis. Clin. N. Am.202010.1016/j.idc.2020.02.003 77.KimJ.-D.OhtaT.TateisiY.TsujiiJ.GENIA corpus--semantically annotated corpus"/>
 <result pre="the number of protein targets associated with them. Figure 5" exact="General" post="scheme of the data extraction and analysis. molecules-25-02944-t001_Table 1Table"/>
 <result pre="that can have a role in both HIV-1 and severe" exact="acute" post="respiratory syndrome (SARS)-coronavirus (CoV-2) infections. Protein Name UniProt ID"/>
 <result pre="can have a role in both HIV-1 and severe acute" exact="respiratory" post="syndrome (SARS)-coronavirus (CoV-2) infections. Protein Name UniProt ID 1"/>
 <result pre="have a role in both HIV-1 and severe acute respiratory" exact="syndrome" post="(SARS)-coronavirus (CoV-2) infections. Protein Name UniProt ID 1 Species"/>
 <result pre="both HIV-1 and severe acute respiratory syndrome (SARS)-coronavirus (CoV-2) infections." exact="Protein" post="Name UniProt ID 1 Species 2 Tissue 3 Process"/>
 <result pre="B P07858 Homo sapiens Widely expressed Entry of the virus" exact="Viral" post="replication (HIV-1) Cathepsin L Q5K630 Homo sapiens Widely expressed"/>
 <result pre="expressed Entry of the virus Complement C3 P01024 Homo sapiens" exact="Blood" post="plasma and over 200 tissues Immune responseInflammationComplement activation IFITM1"/>
</results>
